We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Siemens Healthineers Point of Care Diagnostics

Siemens Healthineers Point-of-Care solutions are designed to provide immediate, convenient, and easy-to-use diagnosti... read more Featured Products: More products

Download Mobile App




New 8-Minute Blood Test to Diagnose or Rule Out Heart Attack Shortens ED Stay

By LabMedica International staff writers
Posted on 03 Sep 2024
Print article
The Atellica VTLi Patient-side Immunoassay Analyzer, a high-sensitivity troponin I test at the bedside, delivers accurate results in just 8 minutes (Photo courtesy of Siemens Healthineers)
The Atellica VTLi Patient-side Immunoassay Analyzer, a high-sensitivity troponin I test at the bedside, delivers accurate results in just 8 minutes (Photo courtesy of Siemens Healthineers)

Emergency department overcrowding is a significant global issue that leads to increased mortality and morbidity, with chest pain being one of the most common reasons for hospital admissions. Most patients with chest pain, who are hospitalized for extended periods for evaluation of acute coronary syndrome (ACS), turn out to have non-threatening causes like gastro-esophageal reflux. This makes accelerated diagnostic protocols, including high-sensitivity cardiac troponin (hs-cTn) tests, crucial for the quick assessment and early discharge of patients at low risk. Traditional hs-cTn testing requires two blood samples spaced 1-3 hours apart, each taking about 60 minutes to process. In contrast, point-of-care (POC) testing can yield faster results. Now, late-breaking research presented at ESC Congress 2024 highlights a new rapid blood test that could improve the treatment for individuals presenting with chest pain in emergency departments.

This research was part of the WESTCOR-POC clinical trial conducted at Haukeland University Hospital (Bergen, Norway), where the safety and efficacy of a novel 0-hour and 1-hour POC hs-cTn test were compared against the standard laboratory hs-cTn testing. The POC hs-cTn test, Atellica VTLi from Siemens Healthineers (Forchheim, Germany), demonstrated similar accuracy to lab tests. The study involved 1,494 adult patients showing symptoms of ACS, randomized to either the new eight-minute POC test (728 patients) or the conventional lab test (766 patients). Both groups had comparable demographics and patients were admitted or discharged according to the judgment of the attending physician.

Results showed that the median emergency department stay was slightly reduced by POC testing—174 minutes versus 180 minutes for the standard group. For patients seen by a physician within 60 minutes, POC testing cut emergency department time by 15 minutes (147 vs 162 minutes). POC testing significantly benefited patients with non-ST-elevation myocardial infarction (NSTEMI), reducing their emergency department stay by 43 minutes (137 vs 180 minutes), thus allowing quicker admission to the cardiac ward. Discharge rates within 3 and 6 hours and the total length of hospital stay were similar between the two groups, as were safety outcomes. There were comparable rates of death, heart attacks, and acute revascularizations within 30 days post-discharge (11.4% POC vs 9.4% lab), and very few adverse events occurred after discharge in both groups (0.8% POC vs 0.5% lab), confirming that both testing methods are safe and effective.

“This simple test only requiring a drop of blood can be performed within 8 minutes without the need for a laboratory,” said author Viola Thulin from Haukeland University Hospital. “Use of point-of-care testing on arrival at hospital has the potential to speed up earlier diagnosis or rule out heart attack and reduce the amount of time some patients spend in the emergency department.”

Related Links:
Haukeland University Hospital

Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
ANCA IFA
Kallestad Autoimmune ANCA IFA Complete Kit
New
Drug Detection Platform
ABSOLUDY Drug Detection Platform

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: Steps and methodology of skin biopsy processing for dSTORM (Photo courtesy of Front. Mol. Neurosci. (2024); DOI: 10.3389/fnmol.2024.1431549)

Super-Resolution Imaging Detects Parkinson's 20 Years Before First Motor Symptoms Appear

Parkinson's disease is the second most common neurodegenerative disorder globally, affecting approximately 8.5 million people today. This debilitating condition is characterized by the destruction of ... Read more

Industry

view channel
Image: The Scopio X100 and X100HT full-field digital cell morphology solution (Photo courtesy of Beckman Coulter)

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Since 2022, Beckman Coulter (Brea, CA, USA) and Scopio Labs (Tel Aviv, Israel) have been working together to accelerate adoption of the next generation of digital cell morphology. Scopio's X100 and X100HT... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.